Dive into an enthralling new episode at the Kahn Center this week, where Dr. Joel Kahn delves into groundbreaking research on Lipoprotein(a). He reveals that, particle for particle, it's significantly more atherogenic than LDL-cholesterol. However, given the higher prevalence of LDL-C particles, focusing on reducing LDL-C remains crucial. Next, Dr. Kahn explores an intriguing study on using high doses of vitamin K2 and D3 to slow down coronary artery calcification.

The episode's highlight is the exciting research on a New Zealand-based product, Calocurb, and its potential to reduce appetite and calorie intake. This discovery is particularly noteworthy as the mechanism mirrors that of injectable drugs like Wegovy and Mounjaro, but Calocurb is available as an affordable oral capsule. Dr. Kahn shares his personal experiences with Calocurb, detailing its impact on his mealtime routines.

Plus, listeners can enjoy a special offer – use the discount code 'Joel10' for savings on their purchase. Discover how Calocurb has been effectively integrated into fasting programs, enhancing their success.

1432: A 2013 Interview with Dave Barry